Trial design and enrolment characteristics of LATA (long-acting treatment in adolescents): A randomised, open-label, non-inferiority, 96-week trial evaluating the virological efficacy, safety, acceptability and quality-of-life of the dual long-acting injectable regimen cabotegravir/ rilpivirine compared to daily oral therapy in virologically suppressed adolescents with HIV-1 infection, aged 12 to

White Rose Research Online (University of Leeds, The University of Sheffield, University of York) 2026 Open access

Read full text
Authors: Diana Anena, Elizabeth Chappell, Rashidah Nazzinda, Cecilia Kiilu, Moses Chitsamatanga, Tiyara Arumugam, Alexandra Green, Cissy Kityo Mutuluuza, Mutsa Bwakura‐Dangarembizi, Abraham Siika, Moherndran Archary, Lungile Jafta
+16 more Stella Namukwaya, Janet Seeley, George Patrick Akabwai, Henry Mugerwa, Lisanne A. H. Bevers, David Burger, Simon Walker, Alasdair Bamford, Annabelle South, Naomi Apoto, Molly Bush, Margaret J. Thomason, Ben Spittle, Deborah Ford, Adeodata Kekitiinwa, Sarah Lilian Pett
Cited by: 0

Abstract

Background Alternatives to daily oral antiretroviral therapy (ART) are important for adolescents with HIV (AHIV) to improve adherence and outcomes. Long-Acting-injectable (LAI) cabotegravir/rilpivirine (CAB/RPV) has demonstrated excellent efficacy and safety and strong patient preference in adults. Methods LATA is an ongoing randomised, open-label, 96-week, non-inferiority trial evaluating the efficacy, safety and acceptability of LAI CAB/RPV vs. daily oral therapy with tenofovir (disoproxil fumarate or alafenamide)/lamivudine/dolutegravir (TLD). Participants are virologically suppressed AHIV aged 12-

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV/AIDS Research and Interventions HIV Research and Treatment

Publication details

Journal / source
White Rose Research Online (University of Leeds, The University of Sheffield, University of York)
Publication date
1 March 2026
Language
EN